Article Dans Une Revue Journal of Infectious Diseases Année : 2019

In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab′)2

Résumé

There is no vaccine or approved therapy against lethal Ebola virus (EBOV). We investigated a proven technology platform to produce polyclonal IgG fragments, F(ab')(2), against EBOV. Horses immunized with nanoparticles harboring surface glycoprotein trimers of EBOV-Zaire/Makona produced anti-Ebola IgG polyclonal antibodies with high neutralization activity. Highly purified equine anti-Ebola F(ab')(2) showed strong cross-neutralization of 2 Zaire EBOV strains (Gabon 2001 and Makona) and in vivo 3 or 5 daily F(ab')(2) intraperitoneal injections provided 100% protection to BALB/c mice against lethal EBOV challenge. Rapid preparation of purified equine anti-Ebola F(ab')(2) offers a potentially efficient therapeutic approach against EBOV disease in humans.
Fichier non déposé

Dates et versions

hal-04927501 , version 1 (03-02-2025)

Identifiants

Citer

Trina Racine, Mélanie Denizot, Delphine Pannetier, Ludovic Nguyen, Anaïs Pasquier, et al.. In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab′)2. Journal of Infectious Diseases, 2019, Journal of Infectious Diseases, 220 (1), pp.41-45. ⟨10.1093/infdis/jiz068⟩. ⟨hal-04927501⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More